Click here for the English blog
→
The provided materials comprehensively summarize the latest research findings regarding the diagnosis and treatment of Alzheimer’s disease as of 2026. In particular, the documents detail the commercialization of biomarker tests such as p-tau217, which boasts high accuracy with a single drop of blood, and the elucidation of brain changes that begin decades before the onset of symptoms. Additionally, they present scientific approaches that overturn conventional wisdom, such as a new therapeutic strategy to prevent the aggregation of tau proteins at an early stage and a perspective that views memory impairment as an “impairment of retrieval.” Furthermore, the text mentions the development of an innovative diagnostic system by research institutions in Japan and the clinical data of the disease-modifying drug lecanemab. Overall, while based on medical evidence, the content emphasizes the importance of early detection and intervention at the initial stage. This series of information highlights the current reality where Alzheimer’s disease is transforming from a “disease of despair” into a “controllable disease.”
source